FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
SWOG Cancer Research Network
Roswell Park Cancer Institute
NRG Oncology
Mayo Clinic
Thomas Jefferson University
University of Nebraska
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
OHSU Knight Cancer Institute
Albert Einstein College of Medicine
University of Nebraska
Barbara Ann Karmanos Cancer Institute
Northwestern University
Roswell Park Cancer Institute